公开(公告)号：US20220184051A1

公开(公告)日：2022-06-16

申请号：US17681132

申请日：2022-02-25

Applicant: Iterion Therapeutics, Inc.

Inventor： Steven David Dykstra ,  Henry Havel ,  Stephen Horrigan ,  Roger Harrison ,  Jeffrey Larson ,  Jonathan Northrup ,  Theodore Laslo ,  Garry Gwozdz

IPC: A61K31/444 ,  A61K9/12 ,  A61P11/00 ,  A61K47/34 ,  A61K47/26

Abstract: Formulations of tegavivint and related compounds, methods of making such formulations and methods of treating various conditions utilizing such formulations.

公开(公告)号：US11324691B2

公开(公告)日：2022-05-10

申请号：US17075217

申请日：2020-10-20

Applicant: VYNE THERAPEUTICS INC.

Inventor： Dov Tamarkin ,  Meir Eini ,  Yohan Hazot ,  Mitchell Shirvan ,  Tal Hetzroni Kedem ,  Rita Keynan

IPC: A61K9/00 ,  A61K9/12 ,  A61K31/65 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/24 ,  A61K47/44 ,  A61K47/46

Abstract: Provided are compositions and methods for treating rosacea and acne. Specifically, a gel or foam composition having a tetracycline antibiotic and uses thereof for treating rosacea and acne are provided.

公开(公告)号：US20220125808A1

公开(公告)日：2022-04-28

申请号：US17493546

申请日：2021-10-04

Applicant: Arctic Nutrition AS

Inventor： Hogne HALLARAKER ,  Jan REMMEREIT ,  Alvin BERGER

IPC: A61K31/661 ,  A23L33/115 ,  A61K31/683 ,  A61K31/685 ,  A23K20/158 ,  A23K50/80 ,  A23K50/60 ,  A61K9/00 ,  A61K47/22 ,  A61K9/06 ,  A61K9/12 ,  A61K47/44 ,  A61K9/20 ,  C11B1/10 ,  A61K31/202

Abstract: The invention provides lipid compositions comprising phospholipids having a high docosahexaenoic acid (DHA) content, which compositions are preferably extracted from natural sources. The lipid compositions are excellent sources of highly bioavailable DHA and they can be used in oral delivery vehicles, dietary supplements, functional foods, and the like.

公开(公告)号：US20220105119A1

公开(公告)日：2022-04-07

申请号：US17330485

申请日：2021-05-26

Applicant: Amcyte Pharma Inc.

Inventor： Julio César Vega

IPC: A61K31/7048 ,  A61K9/12 ,  A61K9/00 ,  A61K47/12 ,  A61K47/10 ,  A61K47/06

Abstract: Formulations and pressurized devices able to get Ivermectin concentrations in the micromolar range in the upper and lower respiratory tract and the oropharyngeal cavity are disclosed. The formulations and devices are used for the prevention or treatment of respiratory diseases caused by SARS CoV 2, such as pandemic COVID 19, and other viruses for which Ivermectin exerts viral inactivation at this concentration range.

公开(公告)号：US11292640B2

公开(公告)日：2022-04-05

申请号：US17021739

申请日：2020-09-15

Applicant: BTG INTERNATIONAL LIMITED

Inventor： Anthony David Harman ,  Jan Willem Marinus Mijers ,  Nikki Robinson

IPC: B65D51/00 ,  A61J1/20 ,  A61K9/12 ,  A61K31/08 ,  B65D47/06 ,  A61J1/14 ,  B65D83/14

Abstract: A device is described for facilitating the preparation of therapeutic foam e.g. for the treatment of varicose veins. A pressurised vial contains a sclerosant liquid, e.g., polidocanol solution, and a sterile gas which is readily absorbed by the body, e.g., carbon dioxide, oxygen or a mixture of these gases. The vial is provided either with a specialised stopper/seal into which a syringe nozzle may be inserted or alternatively a septum seal which may be penetrated by a hypodermic needle. The quantities of gas and liquid and the pressure in the vial are pre-set so that, on connection of a syringe to the vial, a predetermined volume of both gas and liquid is transferred to the syringe, with the intention that the syringe is then used to make a foam by known means. The use of the vial ensures that the ratio of gas to liquid in the foam is standardised, and also provides a convenient way of packaging the gas and liquid and of filling the syringe in a sterile manner.

公开(公告)号：US20220009890A1

公开(公告)日：2022-01-13

申请号：US17301820

申请日：2021-04-15

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Grahame Woollam

IPC: C07D211/62 ,  C07D401/12 ,  A61K9/12 ,  A61K31/4545 ,  A61K45/06 ,  A61K9/16

Abstract: The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.

公开(公告)号：US11213485B2

公开(公告)日：2022-01-04

申请号：US16689611

申请日：2019-11-20

Applicant: CHIESI FARMACEUTICI S.P.A.

Inventor： David Andrew Lewis ,  Brian John Meakin ,  Gaetano Brambilla

IPC: A61K9/00 ,  A61K31/57 ,  A61K31/4745 ,  A61K9/12 ,  A61K31/573 ,  A61P11/00 ,  A61K31/58 ,  A61K45/06 ,  A61K47/10 ,  A61K31/138 ,  A61K31/167 ,  A61K31/4704

Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.

公开(公告)号：US20210379140A1

公开(公告)日：2021-12-09

申请号：US17405491

申请日：2021-08-18

Applicant: Omrix Biopharmaceuticals Ltd. ,  Ethicon, Inc

Inventor： Tamar AUERBACH-NEVO ,  Ashley DEANGLIS ,  Israel Nur

IPC: A61K38/01 ,  A61L26/00 ,  A61L24/00 ,  A61L24/10 ,  A61K9/12 ,  A61K38/36 ,  A61K38/48

Abstract: Provided are pharmaceutical foam compositions comprising a peptone, a peptide hydrolysate or an enzymatically-hydrolyzed protein prepared by enzymatic hydrolysis of a full-length protein; methods of preparation and uses thereof.

公开(公告)号：US20210353542A1

公开(公告)日：2021-11-18

申请号：US17113607

申请日：2020-12-07

Applicant: TDL Innovations LLC

Inventor： Glenn W. Laub

IPC: A61K9/12 ,  A61K47/36 ,  A61K33/18

Abstract: A method for administering an active agent to a pleura of a patient includes preparing a composition including a foamable liquid and the active agent, incorporating a gas into the foamable liquid to create a foam containing the active agent, introducing the foam into a pleural cavity of the patient defined by the pleura, and contacting the pleura with the foam. A method of pleurodesis includes introducing a composition into a pleural cavity defined by pleurae of a patient, the composition including a foamable liquid and an active agent capable of causing inflammation and/or adhesion of the pleurae. A composition for treating a pleura of a patient includes a liquid component including a biocompatible composition having a viscosity which increases in response to an increase in temperature, and an active agent capable of causing inflammation and/or adhesion of the pleura.

公开(公告)号：US11168062B2

公开(公告)日：2021-11-09

申请号：US16332311

申请日：2017-09-12

Applicant: University of Notre Dame du Lac

Inventor： Mayland Chang ,  Shahriar Mobashery ,  Derong Ding

IPC: C07D271/06 ,  C07D413/04 ,  C07D413/12 ,  A61P31/04 ,  C07D413/10 ,  A61K9/20 ,  A61K9/00 ,  A61K9/12 ,  A61K9/48

Abstract: Clostridium difficile infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins that damage the gut. Current therapies for CDI include vancomycin and metronidazole, but neither inhibits spore or toxin production. Thus, recurrence of infection occurs in 25% of patients and there are no antibiotics that are effective for multiple recurrences. We describe oxadiazoles with activity against C. difficile, including the highly virulent NAP1/027 strain with increased production of toxins A and B, as well as the additional binary toxin. Oxadiazole 2 is poorly absorbed, thus advantageously achieving high concentrations in the gut. The compound targets peptidoglycan synthesis and inhibits vegetative cells, spores, and toxin production.